- Home
- PRCT
as 05-09-2025 4:00pm EST
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | SAN JOSE |
| Market Cap: | 2.9B | IPO Year: | 2021 |
| Target Price: | $90.00 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.70 | EPS Growth: | N/A |
| 52 Week Low/High: | $47.04 - $103.81 | Next Earning Date: | 04-24-2025 |
| Revenue: | $249,121,000 | Revenue Growth: | 59.36% |
| Revenue Growth (this year): | 46.28% | Revenue Growth (next year): | 32.67% |
Stock Insider Trading Activity of PROCEPT BioRobotics Corporation (PRCT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Waters Kevin | PRCT | EVP, CFO | Mar 18 '25 | Sell | $57.06 | 733 | $41,824.98 | 107,991 | |
| Nouri Alaleh | PRCT | EVP, CLO, CORP. SEC. | Mar 18 '25 | Sell | $57.06 | 316 | $18,030.96 | 61,473 | |
| Shiblaq Hisham | PRCT | EVP, Chief Comm. Officer | Mar 18 '25 | Sell | $57.06 | 247 | $14,093.82 | 63,133 | |
| Zadno Reza | PRCT | President, CEO | Mar 18 '25 | Sell | $57.06 | 5,475 | $312,403.50 | 173,070 | |
| Waters Kevin | PRCT | EVP, CFO | Mar 6 '25 | Sell | $61.31 | 3,662 | $224,517.22 | 107,991 | |
| Nouri Alaleh | PRCT | EVP, CLO, CORP. SEC. | Mar 6 '25 | Sell | $61.31 | 3,641 | $223,229.71 | 61,473 | |
| Shiblaq Hisham | PRCT | EVP, Chief Comm. Officer | Mar 6 '25 | Sell | $61.31 | 3,588 | $219,980.28 | 63,133 | |
| Zadno Reza | PRCT | President, CEO | Mar 6 '25 | Sell | $61.31 | 15,916 | $975,809.96 | 173,070 |
Latest PROCEPT BioRobotics Corporation News
PRCT Breaking Stock News: Dive into PRCT Ticker-Specific Updates for Smart Investing
GlobeNewswire
10 days ago
PROCEPT BioRobotics® to Attend Four Upcoming Investor Conferences in May & June
Simply Wall St.
11 days ago
Analysts Have Been Trimming Their PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Price Target After Its Latest Report
GlobeNewswire
15 days ago
PROCEPT BioRobotics' Aquablation Therapy Spotlighted at 2025 AUA Annual Meeting Along with Expert-Led Workshops
MT Newswires
15 days ago
Morgan Stanley Cuts Price Target on PROCEPT BioRobotics to $71 From $95, Keeps Overweight Rating
MT Newswires
15 days ago
Procept BioRobotics Q1 Net Loss Narrows, Revenue Increases
Zacks
15 days ago
PROCEPT BioRobotics Corporation (PRCT) Reports Q1 Loss, Tops Revenue Estimates
GlobeNewswire
15 days ago
PROCEPT BioRobotics Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
MT Newswires
a month ago
Truist Cuts Price Target on PROCEPT BioRobotics to $70 From $90, Keeps Buy Rating
Compare PRCT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PRCT PROCEPT BioRobotics Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.